MUMBAI: Biocon and Abraxis BioScience Inc., an integrated global biopharmaceutical company, have announced a licensing agreement for the commercialisation of Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. Under the agreement, Biocon will also have the right to market Abraxane in Pakistan, Bangladesh, Sri Lanka, UAE, Saudi Arabia, Kuwait and certain other Persian Gulf countries.